<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01953770</url>
  </required_header>
  <id_info>
    <org_study_id>ALL-MB 2008</org_study_id>
    <nct_id>NCT01953770</nct_id>
  </id_info>
  <brief_title>Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008</brief_title>
  <acronym>ALL-MB 2008</acronym>
  <official_title>Moscow-Berlin 2008 Multicenter Randomised Study for Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      QUESTIONS AND OBJECTIVES OF ALL-MB-2008 STUDY

        1. Whether the early PEG-asparaginase in induction will lead to the earlier achievement of
           remission, improvement of days 8 and 15 responses leading to an earlier reconstitution
           of bone marrow and immunocompetence, decrease of severe infections and early mortality
           rate?

        2. Whether the use of PEG-asparaginase in induction will allow to avoid the anthracyclines
           in standard risk group patients and to reduce treatment myelotoxicity?

        3. Whether the administration of 9 doses of PEG-asparaginase 1,000 U/m2 instead of 18 doses
           of E.coli L-asparaginase 5,000 U/m2 in standard risk patients will improve treatment
           outcome?

        4. Whether the administrations of high dose methotrexate (2 g/m2 in 24 hours) during 1-st
           consolidation in intermediate risk patients will result in decrease of central nervous
           system relapse incidence and improvement of event-free and overall survival? Whether the
           increase of 6-mercaptopurine starting dose up to 50 mg/m2 in 1-st consolidation phase
           (instead of 25 mg/m2) will decrease in relapse risk, but would not be accompanied with
           enhanced toxicity?

        5. Is it possible to completely avoid the cranial irradiation in intermediate risk
           patients? In some subgroup of intermediate risk patients? Is it enough to control
           neuroleukemia in these patients to introduce additional TIT in the consolidation phase
           of treatment? How will change the possible late effects in these patients according to
           the third arm of randomization?

        6. Will the new risk group stratification to improve overall and event-free survival?
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2008</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>3 years, 5 years and 10 years after study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years, 5 years and 10 years after study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cumulative incidence of relapse</measure>
    <time_frame>3 years, 5 years and 10 years after study start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>early death rate</measure>
    <time_frame>3 years, 5 years and 10 years after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remission death rate</measure>
    <time_frame>3 years, 5 years and 10 years after study start</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Cranial irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consolidation therapy with cranial irradiation in intermediate risk group patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Additional TIT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation therapy with additional triple intrathecal therapy (N6) and without cranial irradiation in intermediate risk group patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTX 2,000 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation therapy with High-dose Methotrexate 2,000 mg/m2/24 h i.v. biweekly in intermediate risk group patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTX 30 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consolidation therapy with Low-dose Methotrexate 30 mg/m2 i.m. weekly in intermediate risk group patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-asp 1,000 U/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation therapy with PEG-L-asparaginase cons 1,000 U/m2 biweekly in standard risk group patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-asp 5,000 U/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consolidation therapy with E.coli L-asparaginase 5,000 U/m2 weekly in standard risk group patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-DNR+</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy without PEG-L-asparaginase and with Daunorubicin 45 mg/m2 in standard and intermediate risk group patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG+DNR+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy)and daunorubicin 45 mg/m2 in standard and intermediate risk group patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG+DNR-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy) without daunorubicin on day 8 in standard risk group patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-L-asparaginase ind</intervention_name>
    <description>1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour</description>
    <arm_group_label>PEG+DNR+</arm_group_label>
    <arm_group_label>PEG+DNR-</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-L-asparaginase cons</intervention_name>
    <description>1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).</description>
    <arm_group_label>PEG-asp 1,000 U/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E.coli L-asparaginase</intervention_name>
    <description>E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).</description>
    <arm_group_label>L-asp 5,000 U/m2</arm_group_label>
    <other_name>Asparaginase Medac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose Methotrexate</intervention_name>
    <description>2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.</description>
    <arm_group_label>MTX 2,000 mg/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose Methotrexate</intervention_name>
    <description>30 mg/Ð¼2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).</description>
    <arm_group_label>MTX 30 mg/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple intrathecal therapy</intervention_name>
    <description>Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).</description>
    <arm_group_label>Additional TIT</arm_group_label>
    <other_name>Methotrexate/Cytarabine/Prednisone i.th.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cranial irradiation</intervention_name>
    <description>12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients &gt;3 years of age</description>
    <arm_group_label>Cranial irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy</description>
    <arm_group_label>PEG-DNR+</arm_group_label>
    <arm_group_label>PEG+DNR+</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age at diagnosis at 1 to 18 years.

          2. The start of induction therapy within a time interval of study recruitment phase.

          3. The diagnosis of ALL is to be proved by the morphological, cytochemical, and
             immunological analysis of tumor cells in bone marrow.

          4. Informed consent of the parents (guardians) of the patient to be treated in one of the
             clinics included in this multicenter study.

        Exclusion Criteria:

          1. ALL is a second malignant tumor;

          2. The disease is a relapse of previously misdiagnosed and, therefore, inadequately
             treated ALL;

          3. There is severe concomitant disease, which significantly impedes chemotherapy protocol
             (such as multiple malformations, heart diseases, metabolic disorders, etc.);

          4. There is a lack of important basic data needed for the exact adherence to the
             cytostatic therapy according to a specific protocol of chemotherapy (differential
             diagnosis of acute lymphoblastic/myeloid leukemia is not possible, stratification
             according to risk group is not possible);

          5. The patient was treated before for a long time with cytotoxic drugs;

          6. There were deviations in the treatment not covered by the protocol and/or not due to
             side effects of treatment and/or complications of the disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander I. Karachunskiy, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of Pediatric Hematology, Oncology and Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Republican Research and Practical Center of Radiation Medicine</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republic Research and Practical Center of Pediatric Oncology and Hematology</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mogilev Regional Children's Hospital</name>
      <address>
        <city>Mogilev</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Children's Hospital</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Hospital</name>
      <address>
        <city>Astrakhan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Regional Cancer Dispensary</name>
      <address>
        <city>Balashikha</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amur Regional Children's Hospital</name>
      <address>
        <city>Blagoveshchensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Children's Clinical Hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irkutsk Regional Children Clinical Hospital</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Clinical Hospital</name>
      <address>
        <city>Khabarovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirov Research Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Hospital</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Territorial Clinical Children Hospital</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Hospital</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republic Children's Clinical Hospital</name>
      <address>
        <city>Makhachkala</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morozov Children's Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Children's Clinic Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republic Children's Clinical Hospital</name>
      <address>
        <city>Nalchik</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Children's Clinic Hospital</name>
      <address>
        <city>Nizhnevartovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Clinic Hospital</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Children's Clinic Hospital â4</name>
      <address>
        <city>Novokuznetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirsk Central District Hospital</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perm Regional Children's Clinic Hospital</name>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Hospital</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov Research Institute of Oncology</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N. Dmitrieva Ryazan Regional Children's Hospital</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Municipal Hospital â1</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Hospital â31</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R. Gorbacheva Research Institute of Pediatric Hematology and Transfusiology; Pavlov State Medical University of Saint-Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Municipal Clinical Hospital â1</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profpathology and Hematology Clinic; Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Clinical Hospital</name>
      <address>
        <city>Stavropol</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgut Central District Clinical Hospital</name>
      <address>
        <city>Surgut</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomsk Regional Clinical Hospital</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tula Regional Children's Hospital</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republic Children's Clinical Hospital</name>
      <address>
        <city>Ulan-Ude</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulyanovsk Regional Children's Clinical Hospital</name>
      <address>
        <city>Ulyanovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Children's City Hospital, Territorial Children's Hematological Center</name>
      <address>
        <city>Vladivostok</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Children Clinical Hospital â1</name>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republic Hospital â1 - National Medicine Centre</name>
      <address>
        <city>Yakutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Clinical Hospital â 1</name>
      <address>
        <city>Yekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Tashkent</city>
        <country>Uzbekistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Russian Federation</country>
    <country>Uzbekistan</country>
  </location_countries>
  <link>
    <url>http://www.mbstudy.net</url>
    <description>Study web-site</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2013</study_first_submitted>
  <study_first_submitted_qc>September 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2013</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</investigator_affiliation>
    <investigator_full_name>Karachunskiy Alexander</investigator_full_name>
    <investigator_title>Deputy director of Research Institute of Pediatric Hematology, Oncology and Immunology</investigator_title>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia, children, adolescents, L-asparaginase, methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

